CDS2

Across TCGA pan-cancer cohorts, CDS2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDS2 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CDS2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDS2 expression acts as an unfavorable survival marker.

BLCA, LUAD, and PRAD are the cancer types where CDS2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.212	0.720	.007	12	view →
LUAD	OS	Median	All	0.186	0.673	.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDS2–BLCA (OS)

Open the BLCA breakdown →